| Jan 8, 2026 | Parabilis Medicines | $305.0M Series F | Jake Simson | Catalio Capital, Foresite Capital, ARCH Venture Partners, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Invus, Marshall Wace, Milky WAY Investments, Nextech Invest, Rock Springs Capital, Sixty Degree Capital, Soleus Capital, T. Rowe Price Associates |
| Dec 16, 2025 | BlossomHill Therapeutics | $84.0M Series B Extension | Brahma Capital, Vish Sridharan | OrbiMed, Plaisance Capital Management, Vivo Capital |
| Nov 20, 2025 | Aspen Neuroscience | $115.0M Series C | ARCH Venture Partners, Frazier Life Sciences, OrbiMed, Revelation Partners | Axon Ventures, Balyasny Asset Management, Cindy Perettie, LifeForce Capital, Lyfe Capital, Medical Excellence Capital, Prebys Ventures Fund, Section 32 |
| Sep 23, 2025 | Ensoma | $53.0M Other Equity | — | 5AM Ventures, Bill & Melinda Gates Foundation, Catalio Capital, Delos Capital, F Prime Capital, Gilead Sciences, Hanwha Impact, Mirae Asset, Qatar Investment Authority, RTW Investments, Solasta Ventures, SymBiosis, Viking Global Investors |
| Sep 1, 2025 | Ensoma | $53.0M Series U | — | 5AM Ventures, Arix Bioscience, Bioluminescence Ventures, F Prime Capital, Bill & Melinda Gates Foundation, Catalio Capital, Delos Capital, Gilead Sciences, Hanwha Impact, Mirae Asset, Qatar Investment Authority, RTW Investments, Solasta Ventures, SymBiosis, Viking Global Investors |
| May 1, 2025 | Antares Therapeutics | $180.0M Series A | Atlas Venture, Shelley CHU, Otello Stampacchia, BVF Partners, Cormorant Asset Management | Frazier Healthcare Partners, Polaris Partners, Vida Ventures, Invus, Tenmile, Vinyanshu Ventures, Willett Advisors, Abingworth |
| May 1, 2025 | Fore Biotherapeutics | $40.0M Series D | — | Roberto DE Ponti, 3B Future Health Ventures (helsinn Investment Fund), HBM Partners, Novartis Venture Fund, Pontifax Venture Capital, SR ONE, 3B Future Health Fund, Medicxi, Novartis, OrbiMed, Wellington Management |
| Oct 1, 2024 | Axonis Therapeutics | $120.0M Series A | Cormorant Asset Management | America's Frontier Fund, BoxOne Ventures, Sierra Ventures, Sofinnova Investments |
| Jul 10, 2024 | Adona Medical | $33.5M Series C | Cormorant Asset Management | — |
| Jul 1, 2024 | Third Arc Bio | $170.0M Series A | Vida Ventures, Cormorant Asset Management, Hillhouse Capital Group | Sofinnova Investments, AbbVie Ventures, Abrdn, BVF Partners, Foresite Capital, Freepoint Capital Group, Goldman Sachs, Janus Henderson Investors, Logos Capital, Marshall Wace, Francesco Draetta, Loretta TSE, T. Rowe Price Associates |
| May 9, 2024 | Aardvark | $85.0M Series C | Victor Tong | Cantor Fitzgerald, Theresa Strong, Laurion Capital Management, LG Technology Ventures, Silver ARC Private Capital, Surveyor Capital, SymBiosis, Tetragon Financial Group, Stacy Ward, Vickers Venture Partners, Walleye Capital |
| May 1, 2024 | AltruBio | $230.0M Series B | Gorjan Hrustanovic | Third Rock Ventures, Alice Zhang, Evan Cheng, Blackstone, Jake Simson, Soleus Capital |
| Mar 1, 2024 | Alumis | $260.0M Series C | Foresite Capital, Srinivas Akkaraju | ARCH Venture Partners, Atlas Venture, Deerfield Management, F Prime Capital, The Column Group, VenBio Partners, Ally Bridge Group, Ayurmaya, HBM Healthcare Investments, Lilly Asia Ventures, Nextech, Omega Funds, Piper Heartland Healthcare Capital, SR ONE |
| Feb 9, 2024 | Neurona Therapeutics | $120.0M Other Equity | Cormorant Asset Management | — |
| Feb 1, 2024 | BioAge Labs | $170.0M Series D | Sofinnova Investments | F Prime Capital, Highbury Group, Johnson & Johnson Innovation, Third Rock Ventures, Uprising, Vzvc, Amgen Ventures, BIO + Health, Lilly Ventures, Patrick Enright, OrbiMed, Osage University Partners, Pivotal BioVenture Partners, RA Capital Management, RTW Investments, Sands Capital, SV Health Investors |
| Feb 1, 2024 | FogPharma | $150.0M Series E | Thilo Schroeder | LUX Capital, Nextech Invest, The Column Group, VenBio Partners, Alex Gorsky, ARCH Venture Partners, Catalio Capital, Farallon Capital Management, Fidelity Management & Research Company, Foresite Capital, General Catalyst, GV, Invus, Marshall Wace, Milky WAY Investments, RA Capital Management, Rock Springs Capital, Samsara BioCapital, Sixty Degree Capital, SymBiosis, T. Rowe Price Associates |
| Dec 1, 2023 | Synnovation Therapeutics | $100.0M Series A | Third Rock Ventures | Johnson & Johnson Innovation, Sofinnova Investments, Judith LI, Thilo Schroeder, Ting Feng |
| Nov 21, 2023 | Supira Medical | $40.0M Series D | Cormorant Asset Management | — |
| Oct 3, 2023 | Akura Medical | $35.0M Series B | Cormorant Asset Management, Gautam Kainth | AMED Ventures, Lilly Asia Ventures, PA MedTech, Unorthodox Ventures |
| Oct 1, 2023 | Triveni Bio | $92.0M Series A | Atlas Venture, Cormorant Asset Management | Polaris Partners |
| Sep 1, 2023 | Star Therapeutics | $90.0M Series C | Sofinnova Investments | Foresite Capital, OrbiMed, Sanofi Ventures, Versant Ventures, Westlake Village BioPartners, Agent Capital, Catalio Capital, Cowen Healthcare Investments, Vijay Lathi, Nybc Ventures, Qatar Investment Authority, Matthew Hammond, Amrit Nagpal, Soleus Capital |
| Aug 1, 2023 | ADARx Pharmaceuticals | $200.0M Series C | Ricky SUN, Chen YU | Andreessen Horowitz, Frazier Healthcare Partners, ED Mathers, OrbiMed, SR ONE, Third Rock Ventures, Ascenta Capital, BlackRock, Commodore Capital, HBM Healthcare Investments, Invus, Lilly Asia Ventures, Redmile Group, T. Rowe Price Associates, Venrock, Vivo Capital |
| May 1, 2023 | OnKure Therapeutics | $54.0M Series C | Surveyor Capital | Acorn Bioventures, Atlas Venture, OrbiMed, BlackRock, Deep Track Capital, Perceptive Advisors, Samsara BioCapital |
| Feb 7, 2023 | Garuda Therapeutics | $62.0M Series B | Cormorant Asset Management | — |
| Feb 1, 2023 | CARGO Therapeutics | $200.0M Series A | Third Rock Ventures, Perceptive Xontogeny Venture Fund, RTW Investments | Ally Bridge Group, Emerson Collective, Janus Henderson Investors, Nextech, Piper Heartland Healthcare Capital, RED Tree Venture Capital, Samsara BioCapital, T. Rowe Price Associates, Wellington Management |
